Getein Biotech, Inc. (603387.SS) researches, develops, manufactures, markets and distributes in vitro diagnostic (IVD) reagents, instruments and analytical medical devices with a focus on point-of-care testing (POCT). The company offers fluorescence immunoassay analyzers and test kits for cardiac markers such as troponin I; chemiluminescence immunoassay systems; clinical chemistry analyzers and reagents; molecular diagnostic kits; thrombus and hemostasis detection products; blood cell analyzers; urine analysis systems; quality control products; and diagnostic raw materials, spanning detection fields including cardiovascular diseases, inflammation, kidney injury, thyroid function, hormones, glucose metabolism, tumors, infectious diseases and coagulation. Getein Biotech, Inc. serves laboratories, emergency rooms, health examination centers, community clinics and personal health management applications primarily in China and internationally across more than 110 countries and territories. Founded in 2002 and headquartered in Nanjing, Jiangsu Province, China, the company maintains leading market share in China's cardiac POCT segment and operates 35 subsidiaries. In recent developments, Getein Biotech showcased advanced diagnostic solutions at the Global Health Exhibition 2025 in Riyadh from October 27-30 and hosted a distributor partners meeting in Antalya, Turkey, on October 29 to strengthen international presence; it continues expansion through OEM/ODM services and certifications including ISO13485 and CE.